Yaky Yanay
2012
In 2012, Yaky Yanay earned a total compensation of $973.7K as Chief Financial Officer at Pluristem Therapeutics, a 13% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $50,175 |
|---|---|
| Salary | $253,752 |
| Stock Awards | $642,500 |
| Other | $27,231 |
| Total | $973,658 |
Yanay received $642.5K in stock awards, accounting for 66% of the total pay in 2012.
Yanay also received $50.2K in non-equity incentive plan, $253.8K in salary and $27.2K in other compensation.
Rankings
In 2012, Yaky Yanay's compensation ranked 6,228th out of 11,487 executives tracked by ExecPay. In other words, Yanay earned more than 45.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,228 out of 11,487 | 46th |
Division Manufacturing | 2,222 out of 4,253 | 48th |
Major group Chemicals And Allied Products | 558 out of 1,198 | 53rd |
Industry group Drugs | 379 out of 920 | 59th |
Industry Biological Products, Except Diagnostic Substances | 62 out of 160 | 61st |
Source: SEC filing on March 29, 2013.
Yanay's colleagues
We found one more compensation record of an executive who worked with Yaky Yanay at Pluristem Therapeutics in 2012.
2012
Zami Aberman
Pluristem Therapeutics
Chief Executive Officer
News
Pluristem Therapeutics CEO Yaky Yanay's 2023 pay jumps 111% to $2.7M
May 1, 2024
Pluristem Therapeutics CEO Yaky Yanay's 2022 pay falls 86% to $1.3M
February 27, 2023
Pluristem Therapeutics Chairman Zami Aberman's 2020 pay falls 54% to $501K
April 8, 2021
Pluristem Therapeutics Chairman Zami Aberman's 2019 pay jumps 85% to $1.1M
May 20, 2020
Pluristem Therapeutics CEO Zami Aberman's 2018 pay falls 83% to $593K
April 25, 2019